Kornimate/medical-research-clean huggingface dataset:
nicotinamide riboside and prevention of cancer therapy related cardiac dysfunction in breast cancer patients

Conditions: Breast Cancer; Metastatic Breast Cancer; Cancer Therapy-Related Cardiac Dysfunction; Cardiotoxicity; Heart Failure

Summary: breast cancer is the most common form of cancer in women. modern breast cancer treatments have led to increased survival, but at the same time, increased risk for cardiotoxicity and development of heart failure. in this study, the investigators want to evaluate whether nicotinamide riboside can prevent cancer-related cardiac dysfunction in metastatic breast cancer patients scheduled for anthracycline therapy. further, the investigators will evaluate change in signs of skeletal muscle injury and functional capacity.

the trial is prospective, randomised, double-blind and placebo-controlled. the primary objective is change in left ventricular ejection fraction (lvef), determined by cardiac mri (cmr). secondary objectives are change in circulating high-sensitivity cardiac troponin i and t (hs-tni and hs-tnt), creatine kinase (ck) and myoglobin, and various measurements of change in left ventricular systolic function determined by cmr and echocardiography. additional assessments are evaluation of the patient's functional capacity and the patients will be asked to fill out questionnaires to assess quality of life. 60 patients will be randomised in a 1:1 ratio. the duration of blinded therapy will depend on the duration of anthracycline therapy. all patients will be examined at baseline and 3 months, and if the patient is scheduled for extended anthracycline therapy, an additional examination will be performed at 6 months.

Eligibility criteria:
inclusion criteria: * women with metastatic breast cancer (stage iv breast cancer) scheduled for anthracycline-containing chemotherapy * eastern cooperative oncology group performance status 0-2 exclusion criteria * age \<18 years * acute myocardial infarction within the last three months * participation in another pharmaceutical clinical trial of an investigational medicinal product (imp) less than 4 weeks prior to inclusion or use of other investigational drugs within 5 half-lives of enrollment, whichever is longer * conditions that would affect the participants to comply with the study protocol as psychiatric or mental disorders, alcohol abuse or other substance abuse, suspected poor drug compliance, language barriers * life expectancy \< 6 months * known allergy to any of the components in the nicotinamide riboside (niagen®) tablet * contraindications or inability to undergo cmr examination

Keywords: breast cancer anthracyclines niagen nicotinamide riboside nicotinamide adenine dinucleotide reactive oxygen species cardiac dysfunction cardio-oncology cardiotoxicity cancer therapy-related cardiac dysfunction
compassionate use of campath-1h in treating patients with refractory prolymphocytic leukemia or chronic lymphocytic leukemia

Conditions: Leukemia

Summary: rationale: monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. compassionate use refers to providing a drug to a patient on humanitarian grounds before the drug has received official approval. purpose: compassionate use of campath-1h in treating patients who have refractory prolymphocytic leukemia or chronic lymphocytic leukemia.

objectives: i. expand access to campath-1h for patients with refractory prolymphocytic leukemia or chronic lymphocytic leukemia. outline: patients receive campath-1h iv over 2 hours on days 1, 3, and 5. treatment repeats weekly for 4-12 weeks in the absence of disease progression or unacceptable toxicity. projected accrual: not specified

Eligibility criteria:
disease characteristics: confirmed prolymphocytic leukemia (pll) or chronic lymphocytic leukemia (cll) pll that has failed at least 1 prior regimen cll that has failed prior fludarabine, defined as: no response disease progression while receiving therapy or relapse within 6 months of completion of last dose patient characteristics: age: 18 and over performance status: who 0-2 life expectancy: not specified hematopoietic: not specified hepatic: bilirubin no greater than 2 times upper limit of normal (uln) (unless secondary to direct liver infiltration with cll) renal: creatinine no greater than 2 times uln other: hiv negative no active infection no other severe concurrent disease no mental disorders no prior allergic reaction to rat or mouse-derived cdr-grafted humanized monoclonal antibodies not pregnant or nursing negative pregnancy test fertile patients must use effective contraception prior concurrent therapy: biologic therapy: not specified chemotherapy: see disease characteristics at least 3 weeks since prior chemotherapy no concurrent cytotoxic therapy endocrine therapy: not specified radiotherapy: at least 3 weeks since prior radiotherapy surgery: not specified

Keywords: refractory chronic lymphocytic leukemia prolymphocytic leukemia
clinical trial with ziprasidone for the treatment of psychiatric pathology associated to alcoholism

Conditions: Depression; Anger; Anxiety; Alcoholism

Summary: alcohol dependent patients show comorbid psychiatric symptoms, related to malfunction of dopamine, norepinephrine and serotonin neurotransmission, during early recovery. ziprasidone can improve malfunctioning of these disregulated systems, thereby improving anxiety, depression, anhedonia, anger, and alcohol craving.

60 alcohol-dependent patients will be included, once finished alcohol detoxification treatment.thirty patients will receive ziprasidone treatment, in progressively increasing doses, starting from 40 mg per day, and the other 30 patients will receive placebo, in a double blind procedure

Eligibility criteria:
inclusion criteria: * dsm-iv-tr criteria for alcohol dependence disorder * age between 18 -65 years old. * score 7 or higher in the ghq-28 scale. exclusion criteria: * more than 30 days without drinking alcohol. * severe medical disorders. * psychotic or bipolar disorders severely decompensated requiring antipsychotic medication. * opiate, cocaine or benzodiazepine dependence disorders, requiring more than one week of detoxification treatment. * pregnant or lactating women

Keywords: psychiatric symptoms associated to alcoholism recovery alcoholism treatment alcohol craving relapse to heavy drinking abuse of other substances during alcoholism recovery
partner: patient reported outcomes and financial toxicity in head and neck cancer a pilot, survey based study

Conditions: Head and Neck Cancer

Summary: the purpose of this single institution, pilot study is to explore the out of pocket (oop)costs and financial toxicity of cancer care for patients during definitive treatment of head and neck cancer with radiation therapy with or without chemotherapy and surgical resection. the study team will assess how the financial burden of cancer care impacts quality of life as well as treatment-related decision-making from a patient perspective.

this is a prospective, single institution, survey-based study to assess oop costs, financial toxicity and pateint reported outcomes (pros') (including qol, quality of care, and attitudes/perspectives on the role of cost in treatment decisions). potential participants are new patient consults in radiation oncology head and neck cancer clinic. patients with an indication for definitive treatment involving radiation therapy will be approached by study staff and, if amenable, enrolled in the study. after signing informed consent, they will complete a baseline survey assessing socioeconomic household information, baseline symptoms/qol and baseline costs/financial toxicity. they will be followed prospectively and re-surveyed at 3 and 6 months after completion of radiation therapy. repeat assessments will document treatment costs and pro including qol, financial toxicity, and self-reported quality of care. patients will be asked to collect all treatment-related bills in a provided binder, which will be reviewed at each survey date. basic demographic data (including age, sex, race, marital status, zip code, and insurance coverage), comorbidities, smoking status, cancer characteristics (stage, site, histology), treatments received, emergency department visits and hospitalization rates at baseline, end of treatment, 3 months and 6 months after radiation treatment will be collected as part of this study. disease status and survival will also be assessed from standard of care follow-up visits up to five years after completion of radiation treatment.

Eligibility criteria:
inclusion criteria: 1. adult (18 years or older) patients 2. diagnosed with hnc with treatment plan including definitive radiation therapy or chemotherapy/radiation therapy 3. be able to read and write in english 4. able to give informed consent and complete survey materials exclusion criteria: 1. recurrent disease 2. metastatic disease 3. prior radiation courses must be approved by pi prior to approaching patient for enrollment (prior systemic therapy is not an exclusion to study enrollment).

Keywords: financial toxicity
acupuncture for anxiety and depression

Conditions: Anxiety and Depression; Breast Cancer Survivor

Summary: the study aims to primarily investigate the effects and safety of acupuncture on anxiety and depression among patients with breast cancer.


Eligibility criteria:
inclusion criteria 1. female, aged 18 to 70 years old; 2. meeting the diagnostic criteria for breast cancer and at tmn i-iii; 3. having completed specialized active treatment for at least one month; 4. with an ecog score of 0-2; 5. mild to moderate anxiety and/or depression; 6. voluntarily joining this study and signing the informed consent form. exclusion criteria (1) starting to take or change the regimen of anti-anxiety and/or -depression disorder medication within one month before enrolment; (2) received psychological intervention or physical therapy one month before enrolment or planning to use in the next 5 months; (3) with diagnosis of anxiety and/or depression disorder prior to the diagnosis of breast cancer; (4) patients with suicidal tendencies, bipolar disorder and psychotic symptoms; (5) patients with severe anxiety and/or depression； (6) patients received acupuncture treatment within one month before enrolment; (7) participating in other clinical studies on the treatment of anxiety and depression; (8) combined with severe underlying diseases; (9) patients with severe skin ulcers; (10) pregnant or lactating patients; (11) poor compliance.
sex differences in gene expression in human adipose tissue

Conditions: Healthy; Obesity

Summary: this project was created to assess sex differences in adipose tissue gene expression in different locations in the body. the primary objectives are to understand: 1. the mechanisms of differential body fat distribution in men and women 2. how body fat distribution is affected by reproductive hormones 3. the mechanisms linking fat distribution to health risks such as diabetes


Eligibility criteria:
inclusion criteria: * caucasian men and women 20-35 years of age * lean (bmi less than 25) * obese (bmi 30-35) exclusion criteria: * hormonal birth control * pregnancy * smokers * history of diabetes, kidney, liver or thyroid disease * history of cancer

Keywords: adipose lean obese overweight healthy
study to test the safety, tolerability and efficacy of ucb7665 in subjects with moderate to severe myasthenia gravis

Conditions: Myasthenia Gravis

Summary: the purpose of the study is to evaluate the clinical efficacy of ucb7665 as a chronic-intermittent treatment in subjects with generalized myasthenia gravis (mg) who are classified as moderate to severe.


Eligibility criteria:
inclusion criteria: * subject has a well-documented diagnosis of myasthenia gravis (mg) at visit 1 (screening), based on subject history and supported by previous evaluations * subject would currently be considered for treatment with immunological therapy (immunoglobulin/plasma exchange (ivig/plex)) by the investigator * subject has a well-documented record of autoantibodies against anti-acetylcholine receptor (anti-achr) or anti-muscle specific kinase (anti-musk) prior to screening * female subjects must either be: postmenopausal, permanently sterilized or if childbearing potential applicable will use a highly effective method of birth control * male subjects must be willing to use a method of contraception exclusion criteria: * subject has previously received treatment in this study or subject has previously been exposed to ucb7665 * subject has participated in another study of an investigational medicinal product (imp; or a medical device) within the previous 30 days of screening or is currently participating in another study of an investigational medicinal product (imp; or a medical device) * subject has a known hypersensitivity to any components of the imp * subject has a history of hyperprolinemia, since l-proline is a constituent of the ucb7665 imp * subjects with myasthenia gravis (mg) only affecting the ocular muscles * subjects with severe weakness affecting oropharyngeal or respiratory muscles, or who have myasthenic crisis at screening or impending crisis * subject has quantitative myasthenia gravis (qmg) score of \<11 at baseline * subject has a serum total immunoglobulin g (igg) level \<= 6g/l at screening * absolute neutrophil count \<1500 cells/mm\^3 * subject has any medical condition (acute or chronic illness) or psychiatric condition that, in the opinion of the investigator, could jeopardize or would compromise the subject's ability to participate in this study * subject has any laboratory abnormality that, in the opinion of the investigator, is clinically significant, has not resolved at randomization, and could jeopardize or would compromise the subject's ability to participate in this study * subject has received a live vaccination within 8 weeks prior to the baseline visit; or intends to have a live vaccination during the course of the study or within 7 weeks following the final dose of imp * subject has received any experimental biological agent within or outside of a clinical study in the past 3 months or within 5 half-lives prior to baseline (whichever is longer)

Keywords: ucb7665 myasthenia gravis
propofol versus midazolam for lower gastrointestinal endoscopy

Conditions: Cirrhosis, Liver

Summary: propofol versus use of midazolam as sedative agent in patients with liver cirrhosis presented for lower gastrointestinal endoscopy

effect of use of propofol versus use of midazolam as sedative agent in patients with liver cirrhosis presented for lower gastrointestinal endoscopy, randomised controlled trial.

Eligibility criteria:
inclusion criteria: * liver cirrhosis * presented to colonoscopy exclusion criteria: * encephalopathy * hypersensitivity * coagulopathy
investigation of the efficacy of telerehabilitation in patients with rotator cuff tendinopathy

Conditions: Rotator Cuff Injuries; Rotator Cuff Tendinitis

Summary: the goal of this study is to investigate the effect of telerehabilitation in patients with rotator cuff tendinopathy. the main questions it aims to answer are: * is telerehabilitation effective in improving the functional status of patients with rotator cuff tendinopathy? * is telerehabilitation effective in reducing the pain of rotator cuff patients?

patients between the ages of 18-65 who were diagnosed with rotator cuff tendinopathy will be included in the study. patients will be divided into two groups. patients in group 1 will be given a home exercise program. then, the patients will be called 3 times a week and it will be evaluated whether they do their exercises regularly and whether they do it correctly. at the end of the first month, the patients will be evaluated again for functionality and pain. the patients in group 2 will be given a home exercise program and at the end of the first month, the patients will be evaluated again in terms of functionality and pain.

Eligibility criteria:
inclusion criteria: * diagnosis of rotator cuff tendinopathy * being able to do the prescribed exercises * having an access to internet and having a computer or smart phone for telerehabilitation exclusion criteria: * patients with a neurological disease that may affect the effectiveness of exercise * history of fracture in shoulder region * history of surgery in shoulder region * patients with a psychiatric disorder

Keywords: rotator cuff tendinopathy telerehabilitation
pretreatment lymphocyte monocyte ratio on outcome hcc patients

Conditions: Hepatocellular Carcinoma

Summary: to assess the prognostic role of pretreatment lmr in hepatocellular carcinoma(hcc).

the exact molecular mechanisms responsible for the prognostic impact of lymphocyte monocyte ratio in heatocellular carcinoma are unclear.it has been suggested that cross-talk between the inflammatory response and tumor progression play a critical role in the initiation and progression of heatocellular carcinoma. in the tumor microenvironment, inflammatory infiltrates have a large influence on the biological behavior of heatocellular carcinoma. tumor-infiltrating lymphocytes, as representative component of the immune microenvironment ,are implicated in several stages of heatocellular carcinoma progression, and tumor-infiltrating lymphocytes phenotypes may be a predictor for favorable prognosis. conversely, low lymphocyte counts might result in an insufficient immunological reaction, which lead to inferior survival in multiple cancers. monocytes infiltrating tumor tissue are also involved in heatocellular carcinoma development and progression. activated monocytes in heatocellular carcinoma micro environments can trigger and polarize t-cell responses and facilitate inflammation-induced tumor development. tumor-associated macrophages are derived from circulating monocytes. tumor-associated macrophages can accelerate heatocellular carcinoma cell proliferation,tumor-associated angiogenesis, and metastasis. several studies showed that high infiltration of tumor-associated macrophages predicted decreased survival in various cancers.

Eligibility criteria:
inclusion criteria: patients with child a hepatocellular carcinoma. exclusion criteria: * patients with child c hepatocellular carcinoma. * patients with heart failure
completely versus partially guided zygomatic implant

Conditions: Maxillary Deficiency; Alveolar Bone Loss

Summary: the aim of study is evaluation of accuracy of completely versus partially limiting computer generated surgical three-dimensional guides during placement of zygoma implants in patients with atrophic maxillae.

according to world oral health organization (who), losing teeth and arch edentulism is the result of a life long history of oral diseases like advanced dental caries and severe periodontal disease. complete tooth loss estimated global average prevalence is 7% among people aged 20 years and 23% among people aged 60 years or older. tooth loss lead to bone resorption in all direction. non-grafting solutions have been developed to reduce risks, morbidity, and treatment time. these types of treatment are often preferred by patients, considering that they may minimize total treatment time and have less morbidity than staged procedures of grafting solutions.one of non-grafting solutions is the zygomatic implants. zygomatic implants have shown improved clinical results compared with bone grafting in compromised maxillary bone.but the same as any surgical procedure, placing zygomatic implants has potential complication, such as: oro-antral communication, paresthesia or altered sensation of the infra orbital nerve also penetration of the orbital cavity may occur. in order to achieve the optimal position of zygomatic implant, computer-based planning has been introduced with the use of surgical guides. surgical guides are classified according to design concepts for fabrication of surgical guide to non-limiting, partially limiting design and complete limiting. in partially limiting design,the first drill is used then the surgical guide is removed and the osteotomy and implant placement are completed in freehand while in complete limiting design all the instruments used in surgical procedure during implant placement are restricted. in literature, there is low evidence of using partially guided surgery for zygomatic implant and also of comparing the two designs with each other. the aim of study is evaluation of accuracy of completely versus partially limiting computer generated surgical three-dimensional guides during placement of zygoma implants in patients with atrophic maxillae.

Eligibility criteria:
inclusion criteria: 1. patients older than 18 years. 2. patients with severe alveolar bone atrophy in posterior maxilla (residual alveolar crest less than 4 mm in height, in the area immediately distal to the canine pillar). exclusion criteria: 1. patients with systemic conditions contra-indicating general anesthesia. 2. patients with conditions contraindicating implant placement (e.g.: radiation to the head and neck, intra-venous bisphosphonates, uncontrolled diabetes mellitus). 3. patients with acute maxillary sinus infection or maxillary sinus cyst. 4. restricted mouth opening (less than 3 cm inter-arch distance anteriorly).

Keywords: zygomatic implant guided surgery deficient maxilla
relapse predicting model for first episode depression

Conditions: Major Depressive Disorders

Summary: major depressive depression(mdd) is an severe public mental disorders. the purpose of current study is using big data analysis based on clinical features and immunochemistry to investigate and establish an relapse predict model for patients with first episode mdd.

major depressive depression(mdd) is an severe public mental disorders. the purpose of current study is using big data analysis based on clinical features and immunochemistry to investigate and establish an relapse predict model for patients with first episode mdd. this study includes two steps. step 1: big data analysis based on the clinical features and immunochemical figures of 30000 patients with first episode mdd will be conducted to construct a relapse predict model. step 2: 300 patients with first episode mdd will be recruited in this step. physicians prefer to give corresponding treatment recommendation based on the predictive factors to verify this relapse model.

Eligibility criteria:
inclusion criteria: * age from 18 to 65 years old; * han chinese; * outpatient and inpatient patients; * patients met diagnostic and statistical manual of mental disorders(dsm-iv-tr) criteria of bipolar i or ii disorder, currently depressed, ascertained with the mini international neuropsychiatric interview (mini) * hamilton depression scale(ham-d) total score≥17, ham-d item 1 (depressed mood) score≥2, and young mania rating scale(ymrs) total score≤10 at baseline; * written informed consent was given; * junior high school education and above, with enough audio-visual ability to accomplish the visits; * normally resident in one country and had a residential address, able to follow-up. exclusion criteria: * bipolar disorder rapid cycling or mixed episode; * experienced dsm-iv-tr axis i disorders in the 6 months prior to randomization; * severe personality disorder, metal retardation, anorexia/bulimia nervosa; * actively suicide ascertained by research psychiatrist or ham-d item 3 score≥3(suicidality); * female patients who were pregnant, planning to be pregnant or breast feeding; * severe medical or neurological problems.

Keywords: mdd big data analytics